What is the current target price for the Yumanity Therapeutics Inc share?

The average Yumanity Therapeutics Inc target price is $13.50. This is 2,443.81% higher than the current share price. 1 Analyst has issued a Yumanity Therapeutics Inc price target 2025.

How high will the Yumanity Therapeutics Inc share rise?

No reliable answer can be given as to how high the Yumanity Therapeutics Inc share will rise. The performance of shares, including the Yumanity Therapeutics Inc share, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Yumanity Therapeutics Inc share today?

The performance of Yumanity Therapeutics Inc shares on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Yumanity Therapeutics Inc share fall?

The decline in Yumanity Therapeutics Inc shares may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's share price could be in a certain period of time, usually 12 months.

Yumanity Therapeutics Inc Forecast, price target & analysts

$0.53

6.89%

Nasdaq, Fri, Jun 28 2024

ISIN

US98872L1026

Symbol

YMTX

Reports

Quarter | Year

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Yumanity Therapeutics Inc Target price 2024 - Analyst rating & recommendation

Yumanity Therapeutics Inc Classifications & Recommendation:

Buy

100%

Yumanity Therapeutics Inc Target price

Target price	$13.50
Course	$0.53
Price potential	2,443.81% register free of charge
Number of estimates	1

	1 Analyst has issued a Yumanity Therapeutics Inc price target 2025. The average Yumanity Therapeutics Inc target price is $13.50. This is 2,443.81% register free of charge higher than the current share price.
	A rating was issued by 1 analysts: 1 Analysts recommend Yumanity Therapeutics Inc to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst estimates: Analysts believe that the Yumanity Therapeutics Inc share has an average upside potential 2025 of 2,443.81% register free of charge . Most analysts recommend the Yumanity Therapeutics Inc share at Purchase.

Earnings per share, P/E ratio and EV/sales forecast 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '23	2024 Forecast
Earnings per share $	-1.28	-1.41
	90.05%	10.16%
P/E ratio		negative

1 Analysts have issued a Yumanity Therapeutics Inc forecast for earnings per share. The average Yumanity Therapeutics Inc <a href=/blog/eps>EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2023. The highest <a href=/blog/eps>EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth figures and future valuations:

2023	$-1.28	90.05%
2024	$-1.41 10.16% unlock
2025	$-1.35 4.26% unlock

Current	-0.34	240.00%
2024	-0.41 20.59% unlock
2025	-0.43 4.88% unlock

Yumanity Therapeutics Inc...

Discover more stocks with a high price target

Valneva 193.86%

CureVac N.V. 152.91%

Plug Power Inc. 106.89%

Bavarian Nordic 55.50%

Teamviewer 54.84%

Zalando 48.21%

Alibaba Group Holding Ltd 45.34%

Daimler Truck 44.32%

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

Start now